Keywords: Breast cancer, NCCN Guidelines, Eisai, Halaven, Amgen, Xgeva, Biomarkers

New therapies for metastatic disease addressed in updated NCCN Guidelines for breast cancer

Article | 15 March 2011

Print This

Women with metastatic breast cancer have expanded treatment options for treating the disease and in the prevention of skeletal-related events ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in